欧洲胰岛素药物市场 - 增长、趋势、COVID-19 影响和预测 (2023 - 2028)

市场按产品类型(基础或长效胰岛素、丸剂或速效胰岛素、传统人胰岛素、组合胰岛素和生物仿制胰岛素)和地理位置进行细分。

市场快照

European human insulin market Overview
Study Period: 2016-2027
CAGR: 0 %

Major Players

European human insulin market Key Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and it's growth?

市场概况

预计欧洲人胰岛素市场在预测期内(2019-2024 年)的复合年增长率为 4.3%,预计到 2019 年将达到 45 亿美元。 

  • 糖尿病通常被认为是一种与生活方式有关的疾病。随着时间的推移,随着人口数量的增加,这种疾病的发病率急剧增加。 
  • 欧洲地区所有年龄组的糖尿病患病率都在增加,这主要是由于肥胖、不健康的饮食和缺乏身体活动。 
  • 欧洲自身免疫性 1 型糖尿病的患病率也在上升,据消息称,欧洲患有 1 型糖尿病的儿童人数最多。对儿童 1 型糖尿病总数贡献最大的欧洲国家是英国、俄罗斯联邦和德国。 
  • 这导致对胰岛素的大量需求。虽然 2 型糖尿病患者的治疗是通过口服药物开始的,但由于不健康的生活方式,当血糖水平没有得到有效控制时,也可能需要使用胰岛素。因此,2型糖尿病患者甚至存在对胰岛素的需求。 

报告范围

市场按产品类型(基础或长效胰岛素、丸剂或速效胰岛素、传统人胰岛素、组合胰岛素和生物仿制胰岛素)和地理位置进行细分。

By Drug
Insulin (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Abasaglar (Insulin Glargine)
Bolus or Fast-acting Insulins
NovoRapid\Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
FIASP (Insulin Aspart)
Admelog (Insulin Lispro)
Traditional Human Insulins
Novolin\Actrapid\Insulatard
Humilin
Insuman
Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography
Europe (Value and Volume, 2012-2024)
United Kingdom
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Insulin Combinations
Biosimilar Insulins
Germany
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Insulin Combinations
Biosimilar Insulins
France
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Insulin Combinations
Biosimilar Insulins
Russia
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Insulin Combinations
Biosimilar Insulins
Spain
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Insulin Combinations
Biosimilar Insulins
Italy
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Insulin Combinations
Biosimilar Insulins
Rest of Europe
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Insulin Combinations
Biosimilar Insulins

Report scope can be customized per your requirements. Click here.

主要市场趋势

胰岛素药品价格上涨

  • 胰岛素已经上市几十年了。然而,胰岛素的成本一直是一个主要问题。  
  • 最近的一个例子是, 由于价格压力,德国 Tresiba 退出了, 因为当局表示他们会将长效基础胰岛素的价格与旧的人胰岛素注射剂相提并论。 
  • 尽管欧洲的生物仿制药竞争加剧,胰岛素价格较低,但品牌药物一直是当务之急。 
  • 此外,领先企业已经能够通过对其品牌药物进行渐进式改进来获得多项扩展。
European human insulin market Key Trends

竞争格局

  • 欧洲人胰岛素市场高度整合,三大制造商也在全球市场占有一席之地,其余制造商仍局限于其他本地或特定区域的制造商。
  • 近期参与者之间的并购帮助企业加强了市场占有率。礼来(Eli Lilly)和勃林格殷格翰(Boehringer Ingelheim)共同开发和商业化 Abasaglar(甘精胰岛素)。
  • Biocon 与 Mylan 合作在欧洲市场推出了 Semglee(生物仿制药甘精胰岛素)。 

 

正在开发的胰岛素:

诺和诺德 正在开发首 个每周一次的长效胰岛素 (LAI287), 目前处于 2 期。该胰岛素适用于 1 型和 2 型糖尿病患者。

Eli Lilly 正在开发一种 长效胰岛素-Fc (LY3209590)。“基础胰岛素-Fc”是一种大分子,由与 Fc 域融合的工程化胰岛素组成,旨在提供长效基础特征。LY3209590 正在研究用于治疗糖尿病。

口服胰岛素的药物有望推动市场:

Biocon 正在开发 Insulin Tregopil,一种口服餐时胰岛素片剂,用于治疗 1 型和 2 型糖尿病。速效口服胰岛素可以改善餐后血糖控制,减少副作用并提高依从性,从而有望改变 T1D 管理。

Oramed Pharmaceuticals  Inc. 是一家专注于口服给药系统开发的临床阶段制药公司,正在努力将首个口服胰岛素产品推向市场,从而提供更方便、更有效、更安全的给药方法胰岛素治疗。

 

主要玩家

  1. Novo Nordisk

  2. Sanofi

  3. Eli Lilly

  4. Biocon

*Disclaimer: Major Players sorted in no particular order

Novo Nordisk, Eli Lilly, Sanofi, Biocon

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Insulin (Value and Volume, 2012-2024)

        1. 5.1.1.1 Basal or Long-acting Insulins

          1. 5.1.1.1.1 Lantus (Insulin Glargine)

          2. 5.1.1.1.2 Levemir (Insulin Detemir)

          3. 5.1.1.1.3 Toujeo (Insulin Glargine)

          4. 5.1.1.1.4 Tresiba (Insulin Degludec)

          5. 5.1.1.1.5 Abasaglar (Insulin Glargine)

        2. 5.1.1.2 Bolus or Fast-acting Insulins

          1. 5.1.1.2.1 NovoRapid\Novolog (Insulin Aspart)

          2. 5.1.1.2.2 Humalog (Insulin Lispro)

          3. 5.1.1.2.3 Apidra (Insulin Glulisine)

          4. 5.1.1.2.4 FIASP (Insulin Aspart)

          5. 5.1.1.2.5 Admelog (Insulin Lispro)

        3. 5.1.1.3 Traditional Human Insulins

          1. 5.1.1.3.1 Novolin\Actrapid\Insulatard

          2. 5.1.1.3.2 Humilin

          3. 5.1.1.3.3 Insuman

        4. 5.1.1.4 Insulin Combinations

          1. 5.1.1.4.1 NovoMix (Biphasic Insulin Aspart)

          2. 5.1.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. 5.1.1.4.3 Xultophy (Insulin Degludec and Liraglutide)

          4. 5.1.1.4.4 Soliqua/Suliqua (Insulin Glargine and Lixisenatide)

        5. 5.1.1.5 Biosimilar Insulins

          1. 5.1.1.5.1 Insulin Glargine Biosimilars

          2. 5.1.1.5.2 Human Insulin Biosimilars

    2. 5.2 Geography

      1. 5.2.1 Europe (Value and Volume, 2012-2024)

        1. 5.2.1.1 United Kingdom

          1. 5.2.1.1.1 Basal or Long-acting Insulins

          2. 5.2.1.1.2 Bolus or Fast-acting Insulins

          3. 5.2.1.1.3 Traditional Human Insulins

          4. 5.2.1.1.4 Insulin Combinations

          5. 5.2.1.1.5 Biosimilar Insulins

        2. 5.2.1.2 Germany

          1. 5.2.1.2.1 Basal or Long-acting Insulins

          2. 5.2.1.2.2 Bolus or Fast-acting Insulins

          3. 5.2.1.2.3 Traditional Human Insulins

          4. 5.2.1.2.4 Insulin Combinations

          5. 5.2.1.2.5 Biosimilar Insulins

        3. 5.2.1.3 France

          1. 5.2.1.3.1 Basal or Long-acting Insulins

          2. 5.2.1.3.2 Bolus or Fast-acting Insulins

          3. 5.2.1.3.3 Traditional Human Insulins

          4. 5.2.1.3.4 Insulin Combinations

          5. 5.2.1.3.5 Biosimilar Insulins

        4. 5.2.1.4 Russia

          1. 5.2.1.4.1 Basal or Long-acting Insulins

          2. 5.2.1.4.2 Bolus or Fast-acting Insulins

          3. 5.2.1.4.3 Traditional Human Insulins

          4. 5.2.1.4.4 Insulin Combinations

          5. 5.2.1.4.5 Biosimilar Insulins

        5. 5.2.1.5 Spain

          1. 5.2.1.5.1 Basal or Long-acting Insulins

          2. 5.2.1.5.2 Bolus or Fast-acting Insulins

          3. 5.2.1.5.3 Traditional Human Insulins

          4. 5.2.1.5.4 Insulin Combinations

          5. 5.2.1.5.5 Biosimilar Insulins

        6. 5.2.1.6 Italy

          1. 5.2.1.6.1 Basal or Long-acting Insulins

          2. 5.2.1.6.2 Bolus or Fast-acting Insulins

          3. 5.2.1.6.3 Traditional Human Insulins

          4. 5.2.1.6.4 Insulin Combinations

          5. 5.2.1.6.5 Biosimilar Insulins

        7. 5.2.1.7 Rest of Europe

          1. 5.2.1.7.1 Basal or Long-acting Insulins

          2. 5.2.1.7.2 Bolus or Fast-acting Insulins

          3. 5.2.1.7.3 Traditional Human Insulins

          4. 5.2.1.7.4 Insulin Combinations

          5. 5.2.1.7.5 Biosimilar Insulins

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2012-2024)

    2. 6.2 Type-2 Diabetes Population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Novo Nordisk

      2. 7.1.2 Eli Lilly

      3. 7.1.3 Sanofi

      4. 7.1.4 Biocon

    2. 7.2 Company Share Analysis

      1. 7.2.1 Novo Nordisk

      2. 7.2.2 Eli Lilly

      3. 7.2.3 Sanofi

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

Market size and volume of individual drugs provided for every country
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

从 2018 年到 2028 年研究了欧洲胰岛素药物市场。

未来 5 年,欧洲胰岛素药物市场的复合年增长率将超过 4%。

2018 年欧洲胰岛素药物市场价值 55.81 亿美元。

2028 年欧洲胰岛素药物市场价值 69.32 亿美元。

诺和诺德、赛诺菲、礼来、阿斯利康、Biocon 是欧洲胰岛素药物市场的主要公司。

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!